Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients.
Anergy and defective immune responses are characteristic of chronic HIV-1 infection. The programmed death 1 (PD-1)/PD-1 ligand (PD-L1) pathway appears to be involved in downregulating T-cell functionality. We found raised levels of PD-L1 in aviraemic chronically infected HIV-1-positive patients, which may contribute to incomplete immune reconstitution after treatment with HAART.
Rosignoli
Guglielmo
G
Department of Immunology, Imperial College London, Chelsea and Westminster Hospital, London, UK.
Cranage
Alison
A
Burton
Catherine
C
Nelson
Mark
M
Steel
Alan
A
Gazzard
Brian
B
Gotch
Frances
F
Imami
Nesrina
N
D015703:Antigens, CD / Q000032:analysis*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D051017:Apoptosis Regulatory Proteins / Q000032:analysis*; D060890:B7-H1 Antigen; D017252:CD3 Complex / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D018655:Lymphocyte Count; D061026:Programmed Cell Death 1 Receptor; D054400:Receptors, CCR7; D019707:Receptors, Chemokine / Q000276:immunology
D015703:Antigens, CD; D051017:Apoptosis Regulatory Proteins; D060890:B7-H1 Antigen; C515370:CCR7 protein, human; C423236:CD274 protein, human; D017252:CD3 Complex; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D054400:Receptors, CCR7; D019707:Receptors, Chemokine